For health and wellness executives, cosmetic manufacturers, pharmaceutical companies, and investors, consumer demand for natural remedies is surging. Cannabidiol (CBD) from industrial hemp offers potential benefits for anxiety, pain, inflammation, and sleep without psychoactive effects. However, regulatory uncertainty, quality control issues, and public misconceptions remain barriers. The solution is Industrial Hemp—original Cannabis plants and extracted products with tetrahydrocannabinol (THC) content below 0.3% (percentage by dry matter weight). This non-psychoactive compound is increasingly used in health and wellness, cosmetics, food & beverage, and pharmaceutical products. This report analyzes this high-growth botanical extract segment, projected to grow at 14.3% CAGR through 2031.
According to the latest release from global leading market research publisher QYResearch, *”Industrial Hemp – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032,”* the global market for Industrial Hemp was valued at US$ 411 million in 2024 and is forecast to reach US$ 1,040 million by 2031, representing a compound annual growth rate (CAGR) of 14.3% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4846945/industrial-hemp
Product Definition – CBD Oil and CBD Crystal
Industrial hemp refers to Cannabis plants and extracted products with THC content below 0.3%. This non-psychoactive compound (CBD) is used in health, wellness, cosmetics, food & beverage, and pharmaceuticals.
Product Types:
CBD Oil (70-75% of market, largest segment): Full-spectrum oil (contains all cannabinoids, terpenes, including trace THC <0.3%). Broad-spectrum oil (multiple cannabinoids, zero THC). CBD isolate (pure CBD, 99%+ purity). Carrier oils: MCT oil (coconut-derived), hemp seed oil, olive oil. Used in tinctures (sublingual drops), capsules, gummies, and topicals (creams, balms). Highest consumer demand (wellness, anxiety, pain, sleep).
CBD Crystal (25-30% of market): Pure CBD isolate (99%+ crystalline powder). No taste, no odor (ideal for formulation). Used in food & beverage (infused drinks, edibles), cosmetics (skincare, lip balms), and pharmaceuticals (clinical-grade). Growing at 15-16% CAGR (faster than oil) as manufacturers prefer pure ingredient for formulation control.
Key Applications:
Medical and Pharmaceutical (40-45% of market, largest segment): Prescription CBD (Epidiolex for rare epilepsy). Over-the-counter CBD for anxiety, pain, inflammation, sleep. Clinical trials for PTSD, schizophrenia, addiction, Parkinson’s. Requires clinical evidence, regulatory approval (FDA, EMA). Highest margins, slowest growth (12-13% CAGR).
Food and Beverage (25-30% of market): CBD-infused gummies, chocolates, mints. Beverages (seltzer, coffee, tea, juice, shots). Baked goods, cooking oils, honey. Regulatory uncertainty (FDA has not approved CBD as food additive). Fastest-growing segment (16-17% CAGR) if regulations clarify.
Cosmetics (15-20% of market): Skincare (serums, moisturizers, cleansers, masks). Lip balms, salves, bath bombs, soaps. Anti-inflammatory, anti-aging claims. Less regulatory scrutiny (cosmetics regulated less strictly than foods/drugs). Growing at 14-15% CAGR.
Other (5-10% of market): Pet products (CBD oil for dogs, cats). Vape cartridges (declining due to regulatory scrutiny). Supplements (capsules, softgels). Topical patches.
Key Industry Characteristics
Characteristic 1: Legalization Expansion Driving Market Growth
More countries and states are legalizing hemp-derived CBD for medical and wellness uses. US (2018 Farm Bill legalized hemp, CBD). EU (Novel Food authorization required, many products approved). Canada (legalized cannabis including CBD). UK (CBD legal as supplement). Brazil, Mexico, Australia, South Korea, Thailand have legalized medical CBD. China allows industrial hemp cultivation (low THC) for export. The 14.3% CAGR reflects ongoing legalization. North America dominates (50-55% of market) but Asia-Pacific and Europe are emerging as high-potential regions (20-25% CAGR).
Characteristic 2: Product Diversification Across Categories
CBD is being integrated into gummies, capsules, beverages, skincare, and pet care. Key drivers include consumer demand for natural wellness (stress, sleep, pain), convenience formats (gummies, beverages easier than tinctures), and brand innovation (differentiation through unique products). Beverages are fastest-growing sub-segment (20-25% CAGR) but face regulatory hurdles (FDA has not approved CBD in beverages). Skincare is established (CBD anti-inflammatory benefits well-known).
Characteristic 3: E-commerce as Key Distribution Channel
Online platforms have become key distribution channels, especially post-COVID-19. E-commerce accounts for 40-45% of CBD sales (highest among supplement categories). Direct-to-consumer (DTC) brands (Charlotte’s Web, CV Sciences) dominate online. Retail (specialty stores, health food stores, pharmacies) accounts for 30-35%. Medical dispensaries (where legal) account for 15-20%. E-commerce enables brand building (customer reviews, education) and subscription models (recurring revenue). E-commerce is growing at 16-17% CAGR.
Characteristic 4: Competitive Landscape – Fragmented with Emerging Leaders
Key players include Kazmira (US – CBD isolate, wholesale), KND Labs (US – bulk CBD), Aurora Cannabis (Canada – medical cannabis, CBD), Canopy Growth Corporation (Canada – CBD, acquisition of US brands), Endoca (Europe – organic CBD), Charlotte’s Web CBD (US – consumer brand, market leader in wellness), CV Sciences (US – PlusCBD brand), Sequoya (US – bulk CBD), Mile High Labs (US – bulk CBD, large-scale extraction), EcoGen Biosciences (US – CBD isolate), Medical Marijuana, Inc. (US), Yunnan Hempson Bio-Tech (China), Tengchong Chenguang Yunma Biotechnology (China). The market is fragmented (top 5 players account for <20% of revenue). Charlotte’s Web and CV Sciences lead consumer brands. Kazmira, Mile High Labs lead wholesale. Chinese manufacturers dominate low-cost CBD production (30-40% lower cost than US/EU). European manufacturers focus on organic, premium.
Exclusive Analyst Observation – The Regulatory Pivot Risk: FDA has not approved CBD as dietary supplement or food additive. Current market operates in regulatory gray area. If FDA issues negative guidance (bans CBD in supplements/food), the food & beverage segment (25-30% of market) would be disrupted. Medical/pharmaceutical segment (40-45%) would continue (FDA-approved drugs). Cosmetics (15-20%) may continue (less regulated). Investors should monitor FDA actions (expected 2025-2026). Companies with pharmaceutical-grade products (clinical trials, FDA interaction) are lower risk.
User Case Example – CBD Gummy Launch (2025)
A wellness brand launched CBD gummies (10mg CBD per gummy, 30 gummies per bottle). Sourcing: CBD isolate (crystal) from Kazmira (US$ 2,000/kg). Gummy manufacturing: US$ 0.10 per gummy. Packaging: US$ 0.50 per bottle. Retail price: US$ 50 per bottle. Gross margin: 70%. The brand sold 100,000 bottles in first year (US$ 5 million revenue). E-commerce channel (brand website, Amazon). Customer acquisition cost: US$ 15 per customer. Repeat purchase rate: 35%. The brand succeeded due to clean labeling (vegan, gluten-free, non-GMO), third-party testing (potency, purity), and influencer marketing (wellness bloggers) (source: brand annual report, 2025).
Technical Pain Points and Recent Innovations
Regulatory Uncertainty: FDA has not issued clear regulations for CBD in supplements/food. Recent innovation: Self-regulation (industry groups pushing for standards). Third-party certification (USP, NSF). Clinical trials (generate safety data). Companies compliant with cGMP (current Good Manufacturing Practices) have competitive advantage.
Quality Control and Standardization: Inconsistent product quality due to lack of uniform manufacturing standards. Recent innovation: ISO 17025 testing labs (potency, pesticides, heavy metals, residual solvents). Batch-to-batch consistency testing. QR code to lab results (consumer transparency). Premium brands provide certificates of analysis (COA) for each batch.
High Extraction Cost: Advanced processing (CO₂ extraction) is costly (US$ 500,000-2 million equipment). Recent innovation: Ethanol extraction (lower cost, suitable for large volume). Hydrocarbon extraction (butane, propane) for full-spectrum oil. Contract manufacturing (outsource extraction). Chinese manufacturers have lower labor and equipment costs.
Recent Policy Driver – EU Novel Food Authorization (2025): CBD products require Novel Food authorization to be sold legally in EU. Authorized products have higher credibility. Non-authorized products face removal from market. This favors larger manufacturers with resources to submit dossiers (safety data, stability studies).
Segmentation Summary
Segment by Type (Product Form): CBD Oil (70-75% of market) – tinctures, capsules, topicals. Largest segment. CBD Crystal (25-30%) – pure isolate, for formulation. Fastest-growing (15-16% CAGR).
Segment by Application: Medical and Pharmaceutical (40-45% of market) – largest segment, prescription and OTC. Food and Beverage (25-30%) – gummies, beverages, edibles. Fastest-growing (16-17% CAGR) but regulatory risk. Cosmetics (15-20%) – skincare, lip balms, bath. Other (5-10%) – pet products, vape, supplements.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
